Ultragenyx Pharmaceutical Inc (RARE):企業の財務・戦略的SWOT分析

GlobalDataが発行した調査報告書(DATA904C3059)
◆英語タイトル:Ultragenyx Pharmaceutical Inc (RARE) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C3059
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年8月
◆ページ数:54
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,375見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,125見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Ultragenyx Pharmaceutical Inc (RARE) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ultragenyx Pharmaceutical Inc (Ultragenyx) is a biotechnology company that develops life-enhancing therapeutics for rare and ultra-rare genetic diseases. Its only marketed product, Mepsevii (vestronidase alfa) is the first indication approved for the treatment of adults and children with Mucopolysaccharidosis (MPS) VII (Sly syndrome). The company’s pipeline comprises Burosumab (KRN23 or UX023), a fully human monoclonal antibody in Phase 3 for the treatment of X-linked hypophosphatemia (XLH); and Burosumab in Phase 2 for the treatment of tumor-induced osteomalacia (TIO); UX007 in Phase 3 for patients with Glut1 DS; UX007 as an oral administration in Phase 2 for the treatment of LC-FAOD. DTX301, in Phase 2 for the treatment of ornithine transcarbamylase (OTC) deficiency; DTX401 in Phase 1 for the treatment of GSDIa, and DTX201 in Phase 1 for the treatment of hemophilia A. It works in partnership with various academic institutes and biotechnology companies to advance its product candidates. Ultragenyx is headquartered in Novato, California, the US.

Ultragenyx Pharmaceutical Inc Key Recent Developments

Aug 02,2018: Ultragenyx reports second quarter 2018 financial results and corporate update
Aug 02,2018: Certara Software or Services supported 95% of the US FDA novel drug approvals in first half of 2018
May 07,2018: Ultragenyx Reports First Quarter 2018 Financial Results
Feb 20,2018: Ultragenyx Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Update
Jan 29,2018: Ultragenyx Names Camille L. Bedrosian as Chief Medical Officer and Executive Vice President

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Ultragenyx Pharmaceutical Inc – Key Facts 6
Ultragenyx Pharmaceutical Inc – Key Employees 7
Ultragenyx Pharmaceutical Inc – Key Employee Biographies 8
Ultragenyx Pharmaceutical Inc – Major Products and Services 10
Ultragenyx Pharmaceutical Inc – History 11
Ultragenyx Pharmaceutical Inc – Company Statement 13
Ultragenyx Pharmaceutical Inc – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2 – Company Analysis 16
Company Overview 16
Ultragenyx Pharmaceutical Inc – Business Description 17
R&D Overview 17
Ultragenyx Pharmaceutical Inc – Corporate Strategy 19
Ultragenyx Pharmaceutical Inc – SWOT Analysis 20
SWOT Analysis – Overview 20
Ultragenyx Pharmaceutical Inc – Strengths 20
Ultragenyx Pharmaceutical Inc – Weaknesses 21
Ultragenyx Pharmaceutical Inc – Opportunities 22
Ultragenyx Pharmaceutical Inc – Threats 23
Ultragenyx Pharmaceutical Inc – Key Competitors 24
Section 3 – Company Financial Ratios 25
Financial Ratios – Capital Market Ratios 25
Financial Ratios – Annual Ratios 26
Performance Chart 28
Financial Performance 28
Financial Ratios – Interim Ratios 29
Financial Ratios – Ratio Charts 30
Section 4 – Company’s Lifesciences Financial Deals and Alliances 31
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32
Ultragenyx Pharmaceutical Inc, Recent Deals Summary 33
Section 5 – Company’s Recent Developments 34
Aug 02, 2018: Ultragenyx reports second quarter 2018 financial results and corporate update 34
Aug 02, 2018: Certara Software or Services supported 95% of the US FDA novel drug approvals in first half of 2018 36
Feb 20, 2018: Ultragenyx Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Update 37
Nov 30, 2017: Ultragenyx to Highlight Pipeline at Analyst and Investor Day on December 4 39
Nov 02, 2017: Ultragenyx Reports Third Quarter 2017 Financial Results and Corporate Update 40
Jul 27, 2017: Ultragenyx Reports Second Quarter 2017 Financial Results and Corporate Update 42
May 04, 2017: Ultragenyx Reports First Quarter 2017 Financial Results and Corporate Update 44
Apr 10, 2017: Ultragenyx Appoints Deborah Dunsire, M.D., to Board of Directors 46
Apr 10, 2017: Ultragenyx Appoints Deborah Dunsire, M.D., to Board of Directors 47
Feb 16, 2017: Ultragenyx Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Update 48
Section 6 – Appendix 50
Methodology 50
Ratio Definitions 50
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Ultragenyx Pharmaceutical Inc, Key Facts 6
Ultragenyx Pharmaceutical Inc, Key Employees 7
Ultragenyx Pharmaceutical Inc, Key Employee Biographies 8
Ultragenyx Pharmaceutical Inc, Major Products and Services 10
Ultragenyx Pharmaceutical Inc, History 11
Ultragenyx Pharmaceutical Inc, Subsidiaries 15
Ultragenyx Pharmaceutical Inc, Key Competitors 24
Ultragenyx Pharmaceutical Inc, Ratios based on current share price 25
Ultragenyx Pharmaceutical Inc, Annual Ratios 26
Ultragenyx Pharmaceutical Inc, Annual Ratios (Cont...1) 27
Ultragenyx Pharmaceutical Inc, Interim Ratios 29
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32
Ultragenyx Pharmaceutical Inc, Recent Deals Summary 33
Currency Codes 50
Capital Market Ratios 50
Equity Ratios 51
Profitability Ratios 51
Cost Ratios 52
Liquidity Ratios 52
Leverage Ratios 53
Efficiency Ratios 53

List of Figures
Ultragenyx Pharmaceutical Inc, Performance Chart (2013 - 2017) 28
Ultragenyx Pharmaceutical Inc, Ratio Charts 30
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 32

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Ultragenyx Pharmaceutical Inc (RARE):企業の財務・戦略的SWOT分析(Ultragenyx Pharmaceutical Inc (RARE) - Financial and Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆